Bombay HC directs Centre to decide representation seeking ‘compulsory licenses’ to two patented anti-TB drugs·March 10, 2021
Covid19: Why aren’t you buying all doses; when will you disburse 50% of doses to states; what is the rationale for differential pricing: SC to Centre·April 30, 2021
Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question?·October 8, 2020
Plea filed in SC seeking directions to Centre to issue compulsory licenses for patents on Remdesivir, Favipiravir, Tocilizumab·April 29, 2021
